{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:01:41Z","timestamp":1761606101319,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jchromb.2019.121808","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T11:20:07Z","timestamp":1570188007000},"page":"121808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["An improved extraction protocol for therapeutic dabigatran monitoring using HPLC-MS\/MS"],"prefix":"10.1016","volume":"1130-1131","author":[{"given":"Alexey V.","family":"Kozlov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina V.","family":"Ramenskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry A.","family":"Sychev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Vlasov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyubov M.","family":"Makarenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena S.","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir I.","family":"Gegechkori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snezana","family":"Agatonovic-Kustrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor V.I.","family":"Chistyakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2019.121808_b0005","first-page":"1404","article-title":"Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance","volume":"98","author":"Ahmad","year":"2012","journal-title":"Heart (Br. Cardiac Soc.)"},{"key":"10.1016\/j.jchromb.2019.121808_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2015.00030","article-title":"Anticoagulant treatment of deep vein thrombosis and pulmonary embolism: the present state of the art","volume":"2","author":"Thaler","year":"2015","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.jchromb.2019.121808_b0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2019.121808_b0020","first-page":"129","article-title":"Determination of direct oral anticoagulants from human serum samples","volume":"40","author":"Harenberg","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jchromb.2019.121808_b0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1160\/TH13-03-0202","article-title":"Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS\/MS for the therapeutic monitoring of patients treated with dabigatran etexilate","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.jchromb.2019.121808_b0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.jchromb.2019.121808_b0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jpba.2014.08.011","article-title":"Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography\u2013tandem mass spectrometry","volume":"100","author":"Korostelev","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2019.121808_b0040","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s11094-018-1753-1","article-title":"HPLC-MS\/MS method for determining dabigatran in human blood serum","volume":"51","author":"Rodina","year":"2018","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.jchromb.2019.121808_b0045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jpba.2011.09.018","article-title":"UPLC MS\/MS assay for routine quantification of dabigatran\u2013a direct thrombin inhibitor\u2013in human plasma","volume":"58","author":"Delavenne","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2019.121808_b0050","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/chromsci\/bmw122","article-title":"Characterization of the fluorescent spectra and intensity of dabigatran and dabigatran etexilate: application to HPLC analysis with fluorescent detection","volume":"54","author":"Schwertner","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jchromb.2019.121808_b0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/FTD.0000000000000355","article-title":"Development of an UHPLC-UV-method for quantification of direct oral anticoagulants: apixaban, rivaroxaban, dabigatran, and its prodrug dabigatran etexilate in human serum","volume":"39","author":"Boehr","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2019.121808_b0060","first-page":"39","article-title":"Development and validation of stability-indicating RP-HPLC method for estimation of dabigatran etexilate","volume":"5","author":"Damle","year":"2014","journal-title":"J. Adv. Sci. Res."},{"key":"10.1016\/j.jchromb.2019.121808_b0065","first-page":"173","article-title":"A case of dabigatran-associated acute renal failure","volume":"112","author":"Shafi","year":"2013","journal-title":"WMJ"},{"key":"10.1016\/j.jchromb.2019.121808_b0070","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jchromb.2015.02.042","article-title":"Development and validation of LC\u2013MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma","volume":"989","author":"Nouman","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2019.121808_b0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cca.2018.08.017","article-title":"Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays","volume":"486","author":"Kuhn","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jchromb.2019.121808_b0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1044-0305(03)00574-9","article-title":"Matrix effect in bio-analysis of illicit drugs with LC-MS\/MS: influence of ionization type, sample preparation, and biofluid","volume":"14","author":"Dams","year":"2003","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2019.121808_b0085","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/10826076.2010.484314","article-title":"Matrix effects in liquid chromatography-mass spectrometry","volume":"33","author":"Cappiello","year":"2010","journal-title":"J. Liq. Chrom. Relat. Tech."},{"key":"10.1016\/j.jchromb.2019.121808_b0090","series-title":"International Conference on Harmonization, Geneva, Switzerland","first-page":"11","article-title":"Validation of analytical procedures: text and methodology Q2 (R1)","author":"Guideline","year":"2005"},{"year":"2009","series-title":"Guideline on Bioanalytical Method Validation","author":"CHMP","key":"10.1016\/j.jchromb.2019.121808_b0095"},{"key":"10.1016\/j.jchromb.2019.121808_b0100","unstructured":"Bioanalytical Method Validation Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Silver Spring, 2018."},{"key":"10.1016\/j.jchromb.2019.121808_b0105","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00216-003-2442-8","article-title":"Evaluation of three calibration methods to compensate matrix effects in environmental analysis with LC-ESI-MS","volume":"378","author":"St\u00fcber","year":"2004","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2019.121808_b0110","first-page":"4342","volume":"767","author":"O'Neil","year":"2001","journal-title":"The Merck Index-An Encyclopedia of Chemicals, Drugs, and Biologicals"},{"key":"10.1016\/j.jchromb.2019.121808_b0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejcdt.2014.11.010","article-title":"Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism)","volume":"64","author":"Abdelwahab","year":"2015","journal-title":"Egypt. J. Chest Dis. Tuberc."},{"key":"10.1016\/j.jchromb.2019.121808_b0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219311262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219311262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T22:58:25Z","timestamp":1761605905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023219311262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":24,"alternative-id":["S1570023219311262"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2019.121808","relation":{},"ISSN":["1570-0232"],"issn-type":[{"type":"print","value":"1570-0232"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An improved extraction protocol for therapeutic dabigatran monitoring using HPLC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2019.121808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121808"}}